NBTX

Nanobiotix S.A. NBTX

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,713 of 2,925

Why it scores 22Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$32.59M

Quarter to Dec 31

Net income

$-23.96M

Quarter to Dec 31

Free cash flow

$-33.96M

Quarter to Dec 31

Operating margin

-33.2%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$218.38M total
JOHNSON & JOHNSON
$212.02M0.0%
MORGAN STANLEY
$1.88M+37.3%
JANE STREET GROUP, LLC
$1.21MNew
HRT FINANCIAL LP
$1.03MNew
XTX Topco Ltd
$597.7KNew
Optiver Holding B.V.
$513.9K+1.0%
MARSHALL WACE, LLP
$378.7K+8.7%
CITADEL ADVISORS LLC
$227.8KNew
BNP PARIBAS FINANCIAL MARKETS
$152.5K+13.6%
UBS Group AG
$97.2K-53.6%
ROYAL BANK OF CANADA
$83.0K+19.9%
JPMORGAN CHASE & CO
$61.3KNew
RHUMBLINE ADVISERS
$56.6K-34.2%
GAMMA Investing LLC
$37.1K+19.0%
OSAIC HOLDINGS, INC.
$18.9K0.0%
WELLS FARGO & COMPANY/MN
$7.5K0.0%
Stone House Investment Management, LLC
$2.9KNew
Federation des caisses Desjardins du Quebec
$2.1KNew
NATIONAL BANK OF CANADA /FI/
$4820.0%
See all 19 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

NBTX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Nanobiotix S.A.'s annual filings on SEC EDGAR.

Nanobiotix S.A. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$32.6M$-24.0M-33.2%
FY 2024$-7.2M$-68.1M—
FY 2023$36.2M$-39.7M-74.0%
FY 2022$4.8M$-57.0M—
FY 2021$2.6M$-47.1M—
FY 2020$2.5M$-33.6M—
Source: NBTX filings on SEC EDGAR →

Companies similar to NBTX

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

About Nanobiotix S.A. (NBTX): stock profile, AI score and financials

Nanobiotix S.A. (NBTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NBTX at 22.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,713 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Nanobiotix S.A. reports quarterly revenue of $32.6M, net income of $-24.0M, an operating margin of -33.2%. Top institutional holders of NBTX by reported 13-F value include JOHNSON & JOHNSON, MORGAN STANLEY, JANE STREET GROUP, based on the most recent SEC filings. NBTX trades on the Nasdaq exchange and files with the SEC under CIK 1760854. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nanobiotix S.A. directly from SEC EDGAR.

SEC EDGAR: CIK 1760854 →